clinicalomicsprowebdirectory
News & Features
Topics
Precision Medicine
Translational Research
Molecular Dx
Informatics
Oncology
Patient Care
New Products
Magazine
Multimedia
Webinars
eBooks
Subscribe
Create a Free Account
Log In
Get Clinical OMICs Magazine
Get Clinical OMICs eNewsletters
Get the Clinical OMICs Mobile App
Get Clinical OMICs News from Alexa
Search
Advertise
Magazine Advertising
Website Banner Advertising
eNewsletter Advertising
Lead Generation Campaigns
Email Nurture Campaigns
Custom Content Solutions
About Us
Contact Us
Mary Ann Liebert Publishers
Create a Free Account
Log In
Clinical OMICs – Molecular Diagnostics in Precision Medicine
News & Features
Molecular Dx
Nanomix Gets $570K from BARDA to Develop Rapid, POC COVID-19 Tests
Patient Care
A4 Study: Elevated Amyloid an early Sign of Alzheimer’s Disease
Precision Medicine
BillionToOne Goes Beyond qPCR with Sanger-Based COVID-19 Test
Oncology
Fate Therapeutics’ IO Collaboration with Janssen Could Yield Company $3 Billion
Patient Care
Coronavirus Replication Stopped in 48 Hours in Lab-Grown Cells by Anti-Parasitic…
Topics
All
Precision Medicine
Translational Research
Molecular Dx
Informatics
Oncology
Patient Care
New Products
Molecular Dx
Nanomix Gets $570K from BARDA to Develop Rapid, POC COVID-19 Tests
Patient Care
A4 Study: Elevated Amyloid an early Sign of Alzheimer’s Disease
Precision Medicine
BillionToOne Goes Beyond qPCR with Sanger-Based COVID-19 Test
Oncology
Fate Therapeutics’ IO Collaboration with Janssen Could Yield Company $3 Billion
Magazine
Magazine
Clinical OMICs Magazine Volume 7, Issue No. 2
Magazine
Clinical OMICs Magazine Volume 7, Issue No. 1
Magazine
Clinical OMICs Magazine Volume 6, Issue No. 6
Magazine
Clinical OMICs Magazine Volume 6, Issue No. 5
Magazine
Clinical OMICs Magazine Volume 6, Issue No. 4
Multimedia
All
Webinars
eBooks
eBooks
Clinical Research in a Real-Time Sequencing Age
Precision Medicine
From Bench to Clinic—The Potential of New Sequencing Tools
Precision Medicine
Mainstreaming Precision Oncology
eBooks
Better Understanding of Post-Translation Modifications Driving Innovation
Subscribe
Create a Free Account
Log In
Get Clinical OMICs Magazine
Get Clinical OMICs eNewsletters
Get the Clinical OMICs Mobile App
Get Clinical OMICs News from Alexa
Home
Oncology
Skin Cancer
Skin Cancer
Latest
Latest
Featured posts
Most popular
7 days popular
By review score
Random
Skin Cancer
University of Arizona Gets $6.9M NCI Grant to Study Skin Cancer...
February 6, 2020
Skin Cancer
New Liquid Biopsy Method IDs Melanoma Patients Likely to Relapse
February 4, 2020
Skin Cancer
Targeting Treg Cell Control Protein Enhances Melanoma Immunotherapy
January 8, 2020
Skin Cancer
Single-Cell Transcriptional Analysis Predicts Melanoma Drug Response
October 9, 2019
Skin Cancer
Melanoma Diagnosis Could be More Precise Using miRNA Biomarkers
September 30, 2019
Skin Cancer
Moffitt, Foundation Medicine, Dana-Farber Partner on Genomic Analysis of MCC Patients
August 23, 2019
Skin Cancer
Sophia Genetics Gains CE-IVD Marking for Solid Tumor Solution
April 12, 2019
Skin Cancer
Myriad Genetics Gets Medicare Coverage for myPath Melanoma Test
March 14, 2019
Skin Cancer
Allison, Honjo Share Nobel Prize for Immunotherapy Breakthroughs
October 1, 2018
Skin Cancer
Melanoma Drug Resistance Mechanism and Biomarker Identified
August 24, 2018
Load more
Scroll Up
We use cookies to give you a better experience on clinicalomics.com. By continuing to use our site, you are agreeing to the use of cookies as set in our
privacy policy.
Got it!
Edit with Live CSS
![ArcherDX said its Archer Immunoverse and VariantPlex NGS assays will be used by Ambry toward offering its biopharma customers large-scale immune repertoire analysis and chimeric antigen T-cell receptor (CAR-T) manufacturing characterization and pharmacodynamics. [royaltystockphoto/Getty Images]](https://www.clinicalomics.com/wp-content/uploads/2019/01/1550-324x160.jpeg "Targeting Treg Cell Control Protein Enhances Melanoma Immunotherapy")
![Researchers at The University of Texas MD Anderson Cancer Center have found that a rare resistance mutation first thought to appear in melanoma (pictured) following treatment with a targeted therapy has instead turned out to be hiding in the tumor all along. [Definiens]](https://www.clinicalomics.com/wp-content/uploads/2019/01/1519-324x160.jpeg "Melanoma Diagnosis Could be More Precise Using miRNA Biomarkers")
![Myriad Genetics has received a final local coverage determination for its myPath Melanoma test from the Medicare Administrative Contractor Palmetto GBA MolDx. [Myriad Genetics]](https://www.clinicalomics.com/wp-content/uploads/2019/03/2189-324x160.jpeg "Myriad Genetics Gets Medicare Coverage for myPath Melanoma Test")
